µ¿¹°¿ë ÅëÁõ °ü¸® ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼ : ÀûÀÀÁõº°, Á¦Ç°º°, Åõ¿© °æ·Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Veterinary Pain Management Market Size, Share & Trends Analysis Report By Indication (Osteoarthritis, Postoperative Pain, Others), By Product, By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå
:
1654212
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2025³â 01¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 150 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
µ¿¹°¿ë ÅëÁõ °ü¸® ½ÃÀå ¼ºÀå°ú µ¿Çâ:
Àü ¼¼°è ¼öÀÇÇÐ ÅëÁõ °ü¸® ½ÃÀå ±Ô¸ð´Â 2030³â 38¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 6.80%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â OA °ü·Ã ÅëÁõ °ü¸®¿¡ ÀÖ¾î ´ÜŬ·ÐÇ×üÀÇ µîÀå, °ñ°üÀý¿° µî µ¿¹°ÀÇ Áúº´ À¯º´·ü Áõ°¡, ¹Ý·Áµ¿¹° »çÀ° ¼ö Áõ°¡, ¼öÀÇ»ç ¼ö Áõ°¡, µ¿¹° ÀÇ·áºñ Áõ°¡ µîÀ» ²ÅÀ» ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ FDA·ÎºÎÅÍ ¹Ý·Á°ßÀÇ OA ÅëÁõ Á¶Àý¿¡ ´ëÇÑ »ç¿ë ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¶ÇÇÑ, ¹Ý·Áµ¿¹°ÀÇ Àΰ£È, ¹Ý·Áµ¿¹° Àα¸ Áõ°¡, ´ë±â¾÷ÀÇ ³ë·Â °È, µ¿¹° ÀÇ·áºñ »ó½Â µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¹Ý·Áµ¿¹° º¸ÇèÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¼öÀÇ»çÀÇ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, AVMA¿¡ µû¸£¸é ¹Ì±¹ÀÇ ¼öÀÇ»ç ¼ö´Â ÃÑ 127,131¸íÀÔ´Ï´Ù. ¼öÀÇ»çµéÀº ÇöÀç ±Þ¼º ¶Ç´Â ¸¸¼º ÅëÁõ¿¡ °ü°è¾øÀÌ µ¿¹°ÀÇ ÅëÁõÀ» ½Äº°ÇÏ°í ´ëóÇÒ ¼ö ÀÖ´Â µµ±¸¿Í Áö½ÄÀ» ´õ Àß °®Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, µ¿¹°ÀÇ ÅëÁõ Àνİú °ü¸®¿¡ ´ëÇÑ ¼öÀÇ»ç ±³À°¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ¼öÀǰú´ëÇÐÀº ÅëÁõ °ü¸®¸¦ Ä¿¸®Å§·³¿¡ Æ÷ÇÔ½Ã۰í, ¼öÀÇ»çµéÀº Æò»ý±³À° ÇÁ·Î±×·¥À» ÅëÇØ Ãֽбâ¼ú°ú ¾à¹°À» ½ÀµæÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¼öÀÇÇÐ ÅëÁõ °ü¸® ½ÃÀåÀ» ÁÖµµÇÏ´Â ¼öÀÇ»ç ¼öÀÇ»ç ¼öÀÇ Áõ°¡´Â ´õ ³ªÀº Ä¡·á¿Í µ¿¹°ÀÇ Çʿ信 ´ëÇÑ ÀÌÇØ¿¡ ´ëÇÑ ±àÁ¤ÀûÀÎ º¯È¸¦ ¹Ý¿µÇϸç, ¹Ý·Áµ¿¹°ÀÇ Àΰ£È¿Í Á¤¼Àû, ½ÅüÀû À£ºù¿¡ ´ëÇÑ ÀνÄÀÌ È®»êµÇ´Â Ãß¼¼¿Í ÀÏÄ¡ÇÕ´Ï´Ù.
¼öÀÇ»çÀÇ ÅëÁõ °ü¸®´Â ƯÈ÷ ¾Ï°ú °°ÀÌ ÅëÁõÀÌ ½É°¢ÇÑ Áõ»óÀ¸·Î ³ªÅ¸³ª´Â Áúº´¿¡¼ ¹Ý·Áµ¿¹°À» µ¹º¸´Â µ¥ ÀÖ¾î ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. 10¼¼ ÀÌ»ó ¹Ý·Á°ßÀÇ ¾à 50%°¡ ¾Ï¿¡ °É¸®¸ç, ¹Ý·Á°ßÀÇ ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼öÀÇÇÐ ºÐ¾ß¿¡¼ È¿°úÀûÀÎ ÅëÁõ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °³ÀÇ ¾ÏÀº »ç¶÷°ú ºñ½ÁÇÑ ºñÀ²·Î ¹ß»ýÇÕ´Ï´Ù. ¸²ÇÁÁ¾°ú °°ÀÌ °³º¸´Ù °í¾çÀ̰¡ ´õ ÀÚÁÖ °É¸®´Â ¾Ïµµ ÀÖ½À´Ï´Ù. ¾Ï¿¡ °É¸° ¹Ý·Á°ßÀÇ ÅëÁõ °ü¸®¸¦ µ½±â À§ÇØ ¼öÀÇ»ç´Â ÁøÅëÁ¦, Ç׿°ÁõÁ¦ µîÀÇ ÀǾàǰ°ú ħ¼ú, ¹°¸®Ä¡·á µîÀÇ º¸¿Ï¿ä¹ýÀ» º´ÇàÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.
¶ÇÇÑ, ÁÖ¿ä M&A, Áö¿ª È®Àå, Á¦Ç° Ãâ½Ã µîÀº ½ÃÀå¿¡¼ÀÇ ¹ßÆÇÀ» ¸¶·ÃÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 1¿ù, Ceva´Â ¹Ý·Áµ¿¹° ÷´Ü Ä¡·áÁ¦¸¦ Àü¹®À¸·Î ÇÏ´Â ´ëÇü »ý¸í°øÇÐ ±â¾÷ ½ºÄ«¿ìÆ® ¹ÙÀÌ¿À(Scout Bio)¸¦ ÀμöÇß½À´Ï´Ù. ÀÌ Àμö´Â ¼¼¹Ù°¡ ¹Ý·Áµ¿¹°ÀÇ ¸¸¼ºÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ´ÜŬ·ÐÇ×ü ¹× À¯ÀüÀÚ Ä¡·á¿Í °°Àº ȹ±âÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» È®º¸ÇÒ ¼ö ÀÖ°Ô µÈ Áß¿äÇÑ ÁøÀüÀÔ´Ï´Ù.
µ¿¹° ÅëÁõ °ü¸® ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs) ºÎ¹®Àº 2024³â 85%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀûÀÀÁõº°·Î´Â °ñ°üÀý¿°(OA) ºÐ¾ß°¡ 2024³â 68.11%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
µ¿¹°º°·Î´Â »ý»ê µ¿¹° ºÎ¹®ÀÌ 2024³â 64%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
Åõ¿© °æ·Îº°·Î´Â °æ±¸Á¦°¡ 2024³â 43.55%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
±¸¸Å Çüź°·Î´Â ó¹æÀü ºÎ¹®ÀÌ 2024³â 84.05%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
ÃÖÁ¾ ¿ëµµº°·Î´Â º´¿ø ¹× Ŭ¸®´ÐÀÌ 2024³â 82.49%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.
ºÏ¹Ì´Â 2024³â 39.56%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î µ¿¹° ÅëÁõ °ü¸® ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
½ÃÀå °èÅë Àü¸Á
»óºÎ ½ÃÀå Àü¸Á
º¸Á¶ ½ÃÀå Àü¸Á
½ÃÀå ¿ªÇÐ
½ÃÀå µå¶óÀ̹ö ºÐ¼®
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
½ÃÀå ±âȸ ºÐ¼®
½ÃÀå °úÁ¦ ºÐ¼®
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå ºÐ¼® Åø
¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
PESTEL ºÐ¼®
¹Ý·Áµ¿¹° ÃßÁ¤ °³Ã¼¼ö(ÁÖ¿ä Á¾ ¹× ÁÖ¿ä ±¹°¡º°, 2018-2024³â)
COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Á¦Ç° ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
NSAIDs
¸¶ÃëÁ¦
¿ÀÇÇ¿ÀÀ̵å
±âŸ
Á¦5Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ÀûÀÀÁõ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
°ñ°üÀý¿°(OA)
¼ö¼ú ÈÄ ÅëÁõ
±âŸ
Á¦6Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : µ¿¹° ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : µ¿¹° º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
»ý»êµ¿¹°
¹Ý·Áµ¿¹°
Á¦7Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Åõ¿© °æ·Î ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Åõ¿© °æ·Î º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
ºñ°æ±¸
°æ±¸
±¹¼Ò
Á¦8Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ±¸ÀÔ ¹æ½Ä ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ±¸ÀÔ ¹æ½Ä º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
ó¹æÀü
OTC
Á¦9Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
ºÎ¹® ´ë½Ãº¸µå
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
º´¿ø¡¤Å¬¸®´Ð
±âŸ
Á¦10Àå ¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
Áö¿ª Àü¸Á
¼öÀÇ ÅëÁõ °ü¸® ½ÃÀå : Áö¿ª º¯µ¿ ºÐ¼®°ú ½ÃÀå Á¡À¯À², 2024³â°ú 2030³â
Áö¿ª ¸¶ÄÏÇ÷¹À̽º : Áß¿äÇÑ Æ÷ÀÎÆ®
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
µ§¸¶Å©
³ë¸£¿þÀÌ
½º¿þµ§
¾Æ½Ã¾ÆÅÂÆò¾ç
ÀϺ»
Áß±¹
Àεµ
Çѱ¹
È£ÁÖ
ű¹
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«°øÈ±¹
»ç¿ìµð¾Æ¶óºñ¾Æ
¾Æ¶ø¿¡¹Ì¸®Æ®
Äí¿þÀÌÆ®
Á¦11Àå °æÀï ±¸µµ
½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
ÁÖ¿ä ±â¾÷ °³¿ä
Boehringer Ingelheim
Vetoquinol
Ceva Animal Health Llc
Chanelle Pharma(Exponent)
Elanco
Dechra Pharmaceuticals Llc(EQT Group)
Zoetis
Merck &Co, Inc.
Norbrook
Assisi(Wind Point Partners)
È÷Æ®¸Ê ºÐ¼®/±â¾÷ ½ÃÀå »óȲ ºÐ¼®
ÁÖ¿ä ½ÃÀå ±â¾÷ ¸®½ºÆ®
ksm
¿µ¹® ¸ñÂ÷
Veterinary Pain Management Market Growth & Trends:
The global veterinary pain management market size is expected to reach USD 3.82 billion in 2030 and is projected to grow at a CAGR of 6.80% from 2025 to 2030. The primary drivers of market growth include the advent of monoclonal antibodies in OA associated pain control, rising prevalence of diseases in animals such as osteoarthritis, rising pet ownership, increasing number of veterinarians, and increasing animal health expenditure. In May 2023, Zoetis's Librela mAb received the U.S. FDA approval for use in dog OA pain control. Moreover, pet insurance adoption is increasing due to a number of factors, including pet humanization, a growing pet population, greater initiatives by major companies, and rising veterinary care expenses.
Increasing number of veterinarians is expected to fuel the market growth. For instance, according to AVMA, there were a total of 127,131 vet practitioners in the U.S. veterinarians are now better equipped with tools and knowledge to identify and address pain in animals, whether it's acute or chronic. Moreover, there's a greater emphasis on educating veterinarians about recognizing and managing pain in animals. Veterinary schools are incorporating pain management into their curricula, and continuing education programs keep practicing veterinarians up-to-date on the latest techniques and medications. Overall, the increasing number of veterinarians driving the veterinary pain management market reflects a positive shift towards better care and understanding of animals' needs, aligning with the broader trend of humanizing pets and recognizing their emotional and physical well-being.
Veterinary pain management has become a crucial aspect of pet care, particularly with conditions such as cancer, where pain can be a significant symptom. With the increase in cancer cases among dogs, there's likely a corresponding increase in the demand for effective pain management solutions in veterinary practice. Approximately fifty percent of dogs over the age of ten develop cancer. Cancer in dogs occurs at a rate similar to that of humans. There are certain cancers that affect cats more frequently than dogs, like lymphoma. In order to help manage pain in dogs with cancer, veterinarians frequently combine pharmaceuticals, such as analgesics and anti-inflammatory medicines, with complementary therapies, such as acupuncture and physical therapy.
Furthermore, key mergers and acquisitions, regional expansions, product launches, etc., to increase their foothold in the market. For instance, in January 2024, Ceva acquired Scout Bio, a leading biotechnology firm specializing in advanced therapies for pets. This acquisition marks a substantial advancement for Ceva, granting access to groundbreaking treatments such as monoclonal antibodies and gene therapy aimed to tackle chronic pet diseases.
Veterinary Pain Management Market Report Highlights:
The NSAIDs segment led the market with the largest revenue share of 85% in 2024. and is anticipated to grow at a lucrative CAGR over the forecast period
Based on indication, the osteoarthritis (OA) segment led the market with the largest revenue share of 68.11%in 2024
Based on animal, the production animals segment led the market with the largest with the largest revenue share of 64% in 2024.
Based on route of administration, the oral segment led the market with the largest revenue share of 43.55% in 2024
Based on mode of purchase, the prescription segment led the market with the largest revenue share of 84.05% in 2024
Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 82.49% in 2024
North America dominated the veterinary pain management market with the largest revenue share of 39.56% in 2024
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Market Definitions
1.7. Model Details
1.8. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Veterinary Pain Management Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Evolving Treatment Methodologies
3.2.1.2. Rising Awareness Initiatives
3.2.1.3. Increasing R&D Initiatives
3.2.1.4. Rising Prevalence Of Associated Health Conditions
3.2.2. Market Restraint Analysis
3.2.2.1. Possible Adverse Effects Of Pain Management Medications
3.2.2.2. Intense Regulatory Scrutiny
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Veterinary Pain Management Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political & Legal landscape
3.3.2.2. Economic and Social landscape
3.3.2.3. Technological landscape
3.3.3. Estimated Companion Animal Population, by key species & key countries, 2018-2024
3.3.4. COVID-19 Impact Analysis
Chapter 4. Veterinary Pain Management Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Veterinary Pain Management Market: Product Movement Analysis & Market Share, 2024 & 2030
4.3. NSAIDs
4.3.1. NSAIDs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Anesthetics
4.4.1. Anesthetics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Opioids
4.5.1. Opioids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Veterinary Pain Management Market: Indication Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Veterinary Pain Management Market: Indication Movement Analysis & Market Share, 2024 & 2030
5.3. Osteoarthritis (OA)
5.3.1. Osteoarthritis (OA) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Postoperative Pain
5.4.1. Cats Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Veterinary Pain Management Market: Animal Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Veterinary Pain Management Market: Animal Movement Analysis & Market Share, 2024 & 2030
6.3. Production Animals
6.3.1. Production Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Companion Animals
6.4.1. Companion Animals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Veterinary Pain Management Market: Route of Administration Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Veterinary Pain Management Market: Route of Administration Movement Analysis & Market Share, 2024 & 2030
7.3. Parenteral
7.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Oral
7.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Topical
7.5.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Veterinary Pain Management Market: Mode of Purchase Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Veterinary Pain Management Market: Mode of Purchase Movement Analysis & Market Share, 2024 & 2030
8.3. Prescription
8.3.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. OTC
8.4.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Veterinary Pain Management Market: End Use Estimates & Trend Analysis
9.1. Segment Dashboard
9.2. Veterinary Pain Management Market: End Use Movement Analysis & Market Share, 2024 & 2030
9.3. Hospitals & Clinics
9.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Others
9.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Veterinary Pain Management Market: Regional Estimates & Trend Analysis
10.1. Regional Outlook
10.2. Veterinary Pain Management Market: Regional Movement Analysis & Market Share, 2024 & 2030
10.3. Regional Marketplace: Key Takeaways
10.4. North America
10.4.1. North America Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.2. U.S.
10.4.2.1. Key Country Dynamics
10.4.2.2. U.S. Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.3. Canada
10.4.3.1. Key Country Dynamics
10.4.3.2. Canada Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.4.4. Mexico
10.4.4.1. Key Country Dynamics
10.4.4.2. Mexico Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5. Europe
10.5.1. Europe Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.2. UK
10.5.2.1. Key Country Dynamics
10.5.2.2. UK Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.3. Germany
10.5.3.1. Key Country Dynamics
10.5.3.2. Germany Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.4. France
10.5.4.1. Key Country Dynamics
10.5.4.2. France Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.5. Italy
10.5.5.1. Key Country Dynamics
10.5.5.2. Italy Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.6. Spain
10.5.6.1. Key Country Dynamics
10.5.6.2. Spain Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.7. Denmark
10.5.7.1. Key Country Dynamics
10.5.7.2. Denmark Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.8. Norway
10.5.8.1. Key Country Dynamics
10.5.8.2. Norway Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.5.9. Sweden
10.5.9.1. Key Country Dynamics
10.5.9.2. Sweden Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6. Asia Pacific
10.6.1. Asia Pacific Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.2. Japan
10.6.2.1. Key Country Dynamics
10.6.2.2. Japan Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.3. China
10.6.3.1. Key Country Dynamics
10.6.3.2. China Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.4. India
10.6.4.1. Key Country Dynamics
10.6.4.2. India Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.5. South Korea
10.6.5.1. Key Country Dynamics
10.6.5.2. South Korea Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.6. Australia
10.6.6.1. Key Country Dynamics
10.6.6.2. Australia Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.6.7. Thailand
10.6.7.1. Key Country Dynamics
10.6.7.2. Thailand Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7. Latin America
10.7.1. Latin America Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.2. Brazil
10.7.2.1. Key Country Dynamics
10.7.2.2. Brazil Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.7.3. Argentina
10.7.3.1. Key Country Dynamics
10.7.3.2. Argentina Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.8. Middle East & Africa
10.8.1. Middle East & Africa Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.8.2. South Africa
10.8.2.1. Key Country Dynamics
10.8.2.2. South Africa Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.8.3. Saudi Arabia
10.8.3.1. Key Country Dynamics
10.8.3.2. Saudi Arabia Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.8.4. UAE
10.8.4.1. Key Country Dynamics
10.8.4.2. UAE Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
10.8.5. Kuwait
10.8.5.1. Key Country Dynamics
10.8.5.2. Kuwait Veterinary Pain Management Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 11. Competitive Landscape
11.1. Market Participant Categorization
11.2. Key Company Profiles
11.2.1. Boehringer Ingelheim
11.2.1.1. Company Overview
11.2.1.2. Financial Performance
11.2.1.3. Solutions Benchmarking
11.2.1.4. Strategic Initiatives
11.2.2. Vetoquinol
11.2.2.1. Company Overview
11.2.2.2. Financial Performance
11.2.2.3. Solutions Benchmarking
11.2.2.4. Strategic Initiatives
11.2.3. Ceva Animal Health Llc
11.2.3.1. Company Overview
11.2.3.2. Financial Performance
11.2.3.3. Solutions Benchmarking
11.2.3.4. Strategic Initiatives
11.2.4. Chanelle Pharma (Exponent)
11.2.4.1. Company Overview
11.2.4.2. Financial Performance
11.2.4.3. Solutions Benchmarking
11.2.4.4. Strategic Initiatives
11.2.5. Elanco
11.2.5.1. Company Overview
11.2.5.2. Financial Performance
11.2.5.3. Solutions Benchmarking
11.2.5.4. Strategic Initiatives
11.2.6. Dechra Pharmaceuticals Llc (EQT Group)
11.2.6.1. Company Overview
11.2.6.2. Financial Performance
11.2.6.3. Solutions Benchmarking
11.2.6.4. Strategic Initiatives
11.2.7. Zoetis
11.2.7.1. Company Overview
11.2.7.2. Financial Performance
11.2.7.3. Solutions Benchmarking
11.2.7.4. Strategic Initiatives
11.2.8. Merck & Co, Inc.
11.2.8.1. Company Overview
11.2.8.2. Financial Performance
11.2.8.3. Solutions Benchmarking
11.2.8.4. Strategic Initiatives
11.2.9. Norbrook
11.2.9.1. Company Overview
11.2.9.2. Financial Performance
11.2.9.3. Solutions Benchmarking
11.2.9.4. Strategic Initiatives
11.2.10. Assisi (Wind Point Partners)
11.2.10.1. Company Overview
11.2.10.2. Financial Performance
11.2.10.3. Solutions Benchmarking
11.2.10.4. Strategic Initiatives
11.2.10.5. Strategic Initiatives
11.3. Heat Map Analysis/ Company Market Position Analysis
11.4. List of Key Market Players
°ü·ÃÀÚ·á